Stereotactic body radiation therapy for primary and metastatic liver tumors

A single institution phase i-ii study

Alejandra Méndez Romero, Wouter Wunderink, Shahid Hussain, Jacco A. De Pooter, Ben J.M. Heijmen, Peter C.J.M. Nowak, Joost J. Nuyttens, Rene P. Brandwijk, Cees Verhoef, Jan N.M. Ijzermans, Peter C. Levendag

Research output: Contribution to journalArticle

314 Citations (Scopus)

Abstract

The feasibility, toxicity and tumor response of stereotactic body radiation therapy (SBRT) for treatment of primary and metastastic liver tumors was investigated. From October 2002 until June 2006, 25 patients not suitable for other local treatments were entered in the study. In total 45 lesions were treated, 34 metastases and 11 hepatocellular carcinoma (HCC). Median follow-up was 12.9 months (range 0.5-31). Median lesion size was 3.2 cm (range 0.5-7.2) and median volume 22.2 cm3 (range 1.1-322). Patients with metastases, HCC without cirrhosis, and HCC < 4 cm with cirrhosis were mostly treated with 3 × 12.5 Gy. Patients with HCC ≥4 cm and cirrhosis received 5 × 5 Gy or 3 × 10 Gy. The prescription isodose was 65%. Acute toxicity was scored following the Common Toxicity Criteria and late toxicity with the SOMA/LENT classification. Local failures were observed in two HCC and two metastases. Local control rates at 1 and 2 years for the whole group were 94% and 82%. Acute toxicity grade ≥3 was seen in four patients; one HCC patient with Child B developed a liver failure together with an infection and died (grade 5), two metastases patients presented elevation of gamma glutamyl transferase (grade 3) and another asthenia (grade 3). Late toxicity was observed in one metastases patient who developed a portal hypertension syndrome with melena (grade 3). SBRT was feasible, with acceptable toxicity and encouraging local control. Optimal dose-fractionation schemes for HCC with cirrhosis have to be found. Extreme caution should be used for patients with Child B because of a high toxicity risk.

Original languageEnglish (US)
Pages (from-to)831-837
Number of pages7
JournalActa Oncologica
Volume45
Issue number7
DOIs
StatePublished - Sep 1 2006

Fingerprint

Radiotherapy
Hepatocellular Carcinoma
Liver
Neoplasm Metastasis
Neoplasms
Fibrosis
Dose Fractionation
Melena
Asthenia
Liver Failure
Portal Hypertension
Transferases
Prescriptions
Therapeutics
Infection

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Romero, A. M., Wunderink, W., Hussain, S., De Pooter, J. A., Heijmen, B. J. M., Nowak, P. C. J. M., ... Levendag, P. C. (2006). Stereotactic body radiation therapy for primary and metastatic liver tumors: A single institution phase i-ii study. Acta Oncologica, 45(7), 831-837. https://doi.org/10.1080/02841860600897934

Stereotactic body radiation therapy for primary and metastatic liver tumors : A single institution phase i-ii study. / Romero, Alejandra Méndez; Wunderink, Wouter; Hussain, Shahid; De Pooter, Jacco A.; Heijmen, Ben J.M.; Nowak, Peter C.J.M.; Nuyttens, Joost J.; Brandwijk, Rene P.; Verhoef, Cees; Ijzermans, Jan N.M.; Levendag, Peter C.

In: Acta Oncologica, Vol. 45, No. 7, 01.09.2006, p. 831-837.

Research output: Contribution to journalArticle

Romero, AM, Wunderink, W, Hussain, S, De Pooter, JA, Heijmen, BJM, Nowak, PCJM, Nuyttens, JJ, Brandwijk, RP, Verhoef, C, Ijzermans, JNM & Levendag, PC 2006, 'Stereotactic body radiation therapy for primary and metastatic liver tumors: A single institution phase i-ii study', Acta Oncologica, vol. 45, no. 7, pp. 831-837. https://doi.org/10.1080/02841860600897934
Romero, Alejandra Méndez ; Wunderink, Wouter ; Hussain, Shahid ; De Pooter, Jacco A. ; Heijmen, Ben J.M. ; Nowak, Peter C.J.M. ; Nuyttens, Joost J. ; Brandwijk, Rene P. ; Verhoef, Cees ; Ijzermans, Jan N.M. ; Levendag, Peter C. / Stereotactic body radiation therapy for primary and metastatic liver tumors : A single institution phase i-ii study. In: Acta Oncologica. 2006 ; Vol. 45, No. 7. pp. 831-837.
@article{917392d90f75428ba1859be1c5bd9f1c,
title = "Stereotactic body radiation therapy for primary and metastatic liver tumors: A single institution phase i-ii study",
abstract = "The feasibility, toxicity and tumor response of stereotactic body radiation therapy (SBRT) for treatment of primary and metastastic liver tumors was investigated. From October 2002 until June 2006, 25 patients not suitable for other local treatments were entered in the study. In total 45 lesions were treated, 34 metastases and 11 hepatocellular carcinoma (HCC). Median follow-up was 12.9 months (range 0.5-31). Median lesion size was 3.2 cm (range 0.5-7.2) and median volume 22.2 cm3 (range 1.1-322). Patients with metastases, HCC without cirrhosis, and HCC < 4 cm with cirrhosis were mostly treated with 3 × 12.5 Gy. Patients with HCC ≥4 cm and cirrhosis received 5 × 5 Gy or 3 × 10 Gy. The prescription isodose was 65{\%}. Acute toxicity was scored following the Common Toxicity Criteria and late toxicity with the SOMA/LENT classification. Local failures were observed in two HCC and two metastases. Local control rates at 1 and 2 years for the whole group were 94{\%} and 82{\%}. Acute toxicity grade ≥3 was seen in four patients; one HCC patient with Child B developed a liver failure together with an infection and died (grade 5), two metastases patients presented elevation of gamma glutamyl transferase (grade 3) and another asthenia (grade 3). Late toxicity was observed in one metastases patient who developed a portal hypertension syndrome with melena (grade 3). SBRT was feasible, with acceptable toxicity and encouraging local control. Optimal dose-fractionation schemes for HCC with cirrhosis have to be found. Extreme caution should be used for patients with Child B because of a high toxicity risk.",
author = "Romero, {Alejandra M{\'e}ndez} and Wouter Wunderink and Shahid Hussain and {De Pooter}, {Jacco A.} and Heijmen, {Ben J.M.} and Nowak, {Peter C.J.M.} and Nuyttens, {Joost J.} and Brandwijk, {Rene P.} and Cees Verhoef and Ijzermans, {Jan N.M.} and Levendag, {Peter C.}",
year = "2006",
month = "9",
day = "1",
doi = "10.1080/02841860600897934",
language = "English (US)",
volume = "45",
pages = "831--837",
journal = "Acta Oncologica",
issn = "0284-186X",
publisher = "Informa Healthcare",
number = "7",

}

TY - JOUR

T1 - Stereotactic body radiation therapy for primary and metastatic liver tumors

T2 - A single institution phase i-ii study

AU - Romero, Alejandra Méndez

AU - Wunderink, Wouter

AU - Hussain, Shahid

AU - De Pooter, Jacco A.

AU - Heijmen, Ben J.M.

AU - Nowak, Peter C.J.M.

AU - Nuyttens, Joost J.

AU - Brandwijk, Rene P.

AU - Verhoef, Cees

AU - Ijzermans, Jan N.M.

AU - Levendag, Peter C.

PY - 2006/9/1

Y1 - 2006/9/1

N2 - The feasibility, toxicity and tumor response of stereotactic body radiation therapy (SBRT) for treatment of primary and metastastic liver tumors was investigated. From October 2002 until June 2006, 25 patients not suitable for other local treatments were entered in the study. In total 45 lesions were treated, 34 metastases and 11 hepatocellular carcinoma (HCC). Median follow-up was 12.9 months (range 0.5-31). Median lesion size was 3.2 cm (range 0.5-7.2) and median volume 22.2 cm3 (range 1.1-322). Patients with metastases, HCC without cirrhosis, and HCC < 4 cm with cirrhosis were mostly treated with 3 × 12.5 Gy. Patients with HCC ≥4 cm and cirrhosis received 5 × 5 Gy or 3 × 10 Gy. The prescription isodose was 65%. Acute toxicity was scored following the Common Toxicity Criteria and late toxicity with the SOMA/LENT classification. Local failures were observed in two HCC and two metastases. Local control rates at 1 and 2 years for the whole group were 94% and 82%. Acute toxicity grade ≥3 was seen in four patients; one HCC patient with Child B developed a liver failure together with an infection and died (grade 5), two metastases patients presented elevation of gamma glutamyl transferase (grade 3) and another asthenia (grade 3). Late toxicity was observed in one metastases patient who developed a portal hypertension syndrome with melena (grade 3). SBRT was feasible, with acceptable toxicity and encouraging local control. Optimal dose-fractionation schemes for HCC with cirrhosis have to be found. Extreme caution should be used for patients with Child B because of a high toxicity risk.

AB - The feasibility, toxicity and tumor response of stereotactic body radiation therapy (SBRT) for treatment of primary and metastastic liver tumors was investigated. From October 2002 until June 2006, 25 patients not suitable for other local treatments were entered in the study. In total 45 lesions were treated, 34 metastases and 11 hepatocellular carcinoma (HCC). Median follow-up was 12.9 months (range 0.5-31). Median lesion size was 3.2 cm (range 0.5-7.2) and median volume 22.2 cm3 (range 1.1-322). Patients with metastases, HCC without cirrhosis, and HCC < 4 cm with cirrhosis were mostly treated with 3 × 12.5 Gy. Patients with HCC ≥4 cm and cirrhosis received 5 × 5 Gy or 3 × 10 Gy. The prescription isodose was 65%. Acute toxicity was scored following the Common Toxicity Criteria and late toxicity with the SOMA/LENT classification. Local failures were observed in two HCC and two metastases. Local control rates at 1 and 2 years for the whole group were 94% and 82%. Acute toxicity grade ≥3 was seen in four patients; one HCC patient with Child B developed a liver failure together with an infection and died (grade 5), two metastases patients presented elevation of gamma glutamyl transferase (grade 3) and another asthenia (grade 3). Late toxicity was observed in one metastases patient who developed a portal hypertension syndrome with melena (grade 3). SBRT was feasible, with acceptable toxicity and encouraging local control. Optimal dose-fractionation schemes for HCC with cirrhosis have to be found. Extreme caution should be used for patients with Child B because of a high toxicity risk.

UR - http://www.scopus.com/inward/record.url?scp=33748855420&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748855420&partnerID=8YFLogxK

U2 - 10.1080/02841860600897934

DO - 10.1080/02841860600897934

M3 - Article

VL - 45

SP - 831

EP - 837

JO - Acta Oncologica

JF - Acta Oncologica

SN - 0284-186X

IS - 7

ER -